Citadel Advisors
GANX icon

Citadel Advisors’s Gain Therapeutics GANX Stock Holding History

Citadel Advisors’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.6K Buy
40,700
+26,200
+181% +$48.3K ﹤0.01% 12826
2026
Q1 		$28.1K Sell
14,500
-36,900
-72% -$80.3K ﹤0.01% 12589
2025
Q4 		$166K Buy
51,400
+41,100
+399% +$110K ﹤0.01% 11207
2025
Q3 		$18.2K Buy
+10,300
New +$17.4K ﹤0.01% 12507
2025
Q2 		– Sell
-8,400
Closed -$16K – 13408
2025
Q1 		$16K Buy
8,400
+2,700
+47% +$5.99K ﹤0.01% 13296
2024
Q4 		$12.3K Buy
+5,700
New +$11.4K ﹤0.01% 13508
2024
Q2 		– Sell
-5,600
Closed -$21.1K – 14670
2024
Q1 		$21.1K Buy
5,600
+4,100
+273% +$17K ﹤0.01% 12978
2023
Q4 		$4.9K Sell
1,500
-200
-12% -$556 ﹤0.01% 13473
2023
Q3 		$5.49K Sell
1,700
-15,200
-90% -$57.6K ﹤0.01% 13388
2023
Q2 		$75.7K Buy
16,900
+4,100
+32% +$20K ﹤0.01% 11303
2023
Q1 		$61.7K Buy
+12,800
New +$52.3K ﹤0.01% 11891

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors's GANX Position: Q2 2026 in Review

Citadel Advisors increased its Gain Therapeutics (GANX) stake by 521% in Q2 2026, buying an estimated $239K and bringing the position to 154,524 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #11018.

Citadel Advisors first reported a position in GANX in Q4 2021 and has held it in 12 quarters since. The position peaked at $661K in Q3 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Citadel Advisors held 154,524 shares of Gain Therapeutics worth $314K as of Q2 2026.
  • Citadel Advisors bought 129,624 Gain Therapeutics shares in Q2 2026, an estimated $239K.
  • Gain Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11018 holding.
  • Citadel Advisors first reported a position in Gain Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Citadel Advisors's Gain Therapeutics position peaked at $661K in Q3 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.